Navigation Links
Pioneering research into rare neonatal diseases
Date:8/13/2012

Groundbreaking research into rare neonatal diseases, conducted by the University of Sheffield, is set to improve the treatment of babies who lack the stress hormone cortisol.

A European Union grant, awarded to the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust with pharmaceutical Diurnal Ltd and partners, will assist the development of a novel neonatal formulation of hydrocortisone a steroid drug that is essential for the survival of babies who lack the hormone cortisol.

Known as the stress hormone, cortisol is secreted from the adrenal gland in the body - without it infants cannot survive. Cortisol has a critical role in combating infections or other sources of physical stress such as extreme exercise or surgery.

The most common cause of adrenal insufficiency in neonates is congenital adrenal hyperplasia (CAH). Approximately 1 in every 12,000 children is born with CAH which is a rare genetic disorder that blocks the adrenal glands' ability to synthesise cortisol.

Due to numerous ethical and practical challenges of testing medications, newborns, neonates and infants are often thought to be at a disadvantage when it comes to new medical treatment, because they have to be treated with drugs that were developed for adults.

Professor Richard Ross from the University of Sheffield's Medical School said: "Adrenal insufficiency is a serious condition resulting from a lack of stress hormone cortisol, and untreated patients will die from an adrenal crisis.

"Currently there is no licensed preparation to treat neonates and infants with adrenal insufficiency, and parents have to use crushed adult tablets, which have associated risks of over- and under-treatment. Under-treatment can be potentially lethal, while over-treatment results in growth failure and obesity."

The European collaborative project Treatment of Adrenal Insufficiency in Neonates and Infants (TAIN) Development of Hydrocortisone Preparation for the Treatment of Adrenal Insufficiency in Neonates and Infants, began in December 2011 and involves European leaders in neonatology, paediatric pharmacology and clinical trial methodology, together with a number of small and medium enterprises.

Professor Ross added: "The TAIN project will deliver the first licensed preparation specifically designed for parents to treat their babies with ease of administration, taste masking and appropriately tailored doses.

"As physicians, we are increasingly aware that treatments given as early in life as possible can have an important impact on development and health later in life. TAIN aims to optimise treatment for babies with adrenal insufficiency, and will strengthen paediatric drug evaluation across Europe by building a network of units experienced in clinical research delivering appropriate formulations for neonates and infants."

TAIN coordinator, Martin Whitaker from the University of Sheffield, said: "The funding of the TAIN programme by the European Commission will, for the first time, allow the possibility to develop an effective paediatric medicine for the rare disease adrenal insufficiency.

"The outcomes of TAIN will make a real and significant difference to the loves of young children suffering from this disease, who currently have to rely on unlicensed, sub-optimal medications.

The TAIN project also includes a consortium to monitor all ethical aspects of the research, to ensure that the resulting product will be safe and efficacious for use in children from birth.


'/>"/>

Contact: Amy Pullan
a.l.pullan@sheffield.ac.uk
44-114-222-9859
University of Sheffield
Source:Eurekalert

Related medicine news :

1. NCH CIRP awarded CDC Injury Control Research Center designation, another 5 years
2. Individualized care best for lymphedema patients, MU researcher says
3. UH students spent summer making a difference with hands-on research
4. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
5. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
6. Excellence Initiative winner TU München invests in the future: Young researchers
7. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
8. Clemson researchers collect and reuse enzymes while maintaining bioactivity
9. Genetic Research Sheds Light on Jewish Diaspora
10. Lawson research suggests breast cancer cells have discerning tastes
11. Clemson researcher awarded nearly $245,000 to study automation trust and dependence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: